HACKENSACK MERIDIAN HEALTH

Brett Favre's Parkinson's diagnosis highlights potential links between collision sports and brain disease, with studies suggesting concussions raise Parkinson's risk by over 55%. Favre, who played 20 NFL seasons, discussed his diagnosis during a welfare scandal hearing, noting his belief in a 'breakthrough concussion drug'. Research indicates football increases Parkinson's risk by 61%, with repetitive head impacts linked to precursors of the disease. Neurologists stress multiple risk factors for Parkinson's, cautioning against immediate links to football injuries.

Adam Gourlay, a 911 dispatcher, was diagnosed with advanced acute myeloid leukemia (AML) at 33. After initial chemotherapy, he opted for a clinical trial of the oral medication IDHIFA, which successfully treated his AML. Adam now lives a normal life, returning to work and spending time with his family, while undergoing regular check-ups.

Hackensack University Medical Center became the first to use the HYDROS Robotic System for Aquablation therapy, treating BPH with a heat-free waterjet, offering durable symptom relief and preserving sexual function.

Hackensack University Medical Center became the first to use the HYDROS™ Robotic System for Aquablation® therapy, treating BPH with an AI-powered, heat-free waterjet, offering durable symptom relief and preserving sexual function.

Foresite Capital closes $900M fund for novel therapeutics and biotech. Marea Therapeutics raises $190M for cholesterol-lowering monoclonal antibody. Santa Ana Bio secures $168M for autoimmune and inflammatory disease treatments. Bright Peak Therapeutics raises $107M for therapeutic cytokine synthesis. Alzheon raises $100M for Alzheimer’s Phase 3 program. Amber Therapeutics closes $100M Series A for neuromodulation therapy for urinary incontinence. iOnctura secures $85.8M for uveal melanoma treatment. Elion Therapeutics raises $81M for invasive fungal infections. Vilya announces $71M Series A for computational drug design. Moleculent AB closes $26M Series A for functional biology platform. Canary Speech secures $13M for AI-powered vocal biomarker technology. Fuse Diagnostics raises $2M for point-of-need pathogen diagnostics. Nuclera awarded $1.4M for eProtein discovery system.